ArticleThe oncologist2025
Baseline geriatric 8 (G8) screening tool predicts overall survival in metastatic urothelial carcinoma treated with immune checkpoint inhibitors.
Article in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetastatic urothelial carcinoma (mUC) remains highly lethal despite advances in treatment. There is limited data surrounding the efficacy and toxicity of immune checkpoint inhibitors in treating elderly patients due to the high bar of clinical trial participation. The Geriatric 8 (G8) screening tool is a quick, 8-item questionnaire designed to assess frailty in older adults. This study evaluates the G8 tool's utility in predicting overall survival (OS) and progression-free survival (PFS) in patients with mUC treated with immune checkpoint inhibitors. MATERIALS AND
methodsA retrospective analysis was conducted on 48 mUC patients treated with ICI monotherapy at Winship Cancer Institute between 2016 and 2019. Baseline G8 scores were calculated from clinical notes. Primary outcomes included OS and PFS, analyzed using Kaplan-Meier, Cox proportional hazards models, and multivariate analysis adjusted for demographic and clinical variables.
resultsAn impaired baseline G8 score predicted worse OS but not PFS. The incidence of immune-related adverse events was lower but not statistically significant in patients with impaired G8 scores (HR, 0.31; OR, 0.09-1.14; P = .077).
conclusionThe G8 screening tool effectively predicts OS in older mUC patients treated with ICIs, highlighting its potential utility in clinical decision-making. Frail patients, as identified by the G8, had significantly worse survival outcomes, underscoring the need for tailored therapeutic approaches in this vulnerable population. Further studies are warranted to validate these findings and explore interventions that may improve outcomes for frail, older patients with mUC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.